Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-06-29
Based on 1117 first isolates · ED · Febrile UTI / pyelonephritis · 2024-06-30 → 2025-06-29
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
piperacillin-tazobactam 81 % (79 %–83 %)
Keep for severe or hospital-onset infections.
Not covered: Enterococcus faecalis (9 %), Staphylococcus aureus (3 %), Escherichia coli (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
86 %
n = 88
nitrofurantoin NIT
trend · Escherichia coli not for this site
85 %
83 %
n = 88
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
86 %
n = 88
ciprofloxacin CIP
trend · Escherichia coli
79 %
76 %
n = 88
mecillinam MEC
trend · Escherichia coli not for this site
78 %
83 %
n = 88
ceftriaxone CRO
trend · Escherichia coli
77 %
80 %
n = 88
trimethoprim TMP
trend · Escherichia coli not for this site
74 %
83 %
n = 88
73 %
76 %
n = 88
53 %
49 %
n = 88
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
11 %
n = 88
5 %
2 %
n = 88
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 88

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
10 %
Enterococcus faecalis
9 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.